This Article Full Text Full Text (PDF) All Versions of this Article: 106/7/866    most recent 01.CIR.0000024981.48160.6Dv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mircoli, L. Articles by Ferrari, A. U. Search for Related Content PubMed PubMed Citation Articles by Mircoli, L. Articles by Ferrari, A. U. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Heart Failure Hazardous Substances DB PHENYLEPHRINE PROPRANOLOL HYDROCHLORIDE Related Collections Congestive Animal models of human disease

(Circulation. 2002;106:866.)
© 2002 American Heart Association, Inc.

Basic Science Reports

Preservation of the Baroreceptor Heart Rate Reflex by Chemical Sympathectomy in Experimental Heart Failure

Luca Mircoli, MD; Luigi Fedele, MD; Marica Benetti, MD; Giovanni Battista Bolla, MD; Alberto Radaelli, MD; Stefano Perlini, MD; Alberto U. Ferrari, MD

From the Divisione di Cardiologia (L.M.), Ospedale Maggiore Policlinico IRCCS, Milano; Dipartimento di Medicina (A.U.F., L.F., M.B., G.B.B.), Prevenzione e Biotecnologie Sanitarie; Centro Fisiologia Clinica e Ipertensione, Università di Milano and Milano-Bicocca; Divisione di Cardioriabilitazione (A.R.), Ospedale di Seregno, Az. Osp. Vimercate (MI); and IRCCS S. Matteo (S.P.), Pavia, Italy.

Correspondence to Alberto U. Ferrari, Centro Fisiologia Clinica e Ipertensione, Via F. Sforza, 35, 20122 Milano, Italy. E-mail alberto.ferrari{at}unimib.it

Background— The mechanisms underlying impaired baroreflex sensitivity in congestive heart failure (CHF) are incompletely understood. The purpose of the present study was to test the hypothesis that this alteration depends on the marked degree of sympathetic overactivity known to characterize the CHF syndrome.

Methods and Results— Eight-week-old rats were subjected to induction of postmyocardial infarction CHF obtained by coronary ligation (Lig), chronic chemical sympathectomy by 6-hydroxydopamine (Sx), both interventions (Sx-Lig), or neither intervention (Veh-Sham, sham surgery, and vehicle administration). Four weeks after infarction, in conscious state, baroreflex sensitivity was assessed from the bradycardic responses to graded phenylephrine-induced elevations in blood pressure (BP). Left ventricular (LV) diameter was assessed by echocardiography, and plasma catecholamines were assayed to estimate sympathetic activity. Lungs were eventually excised and weighed (LW). CHF was associated with the following: (1) no changes in BP and heart rate; (2) sympathetic overactivity (norepinephrine, 320.2±53.8 pg/mL for Veh-Lig versus 173.4±20.5 pg/mL for Veh-Sham, P<0.01), prevented by Sx (181.2±35.5 pg/mL for Sx-Lig versus 159.8±33.1 pg/mL for Sx-Sham, P=NS); (3) LV enlargement (10.3±0.7 mm for Veh-Lig versus 6.8±0.6 mm for Veh-Sham, P<0.01), irrespective of Sx (9.7±0.7 mm for Sx-Lig versus 6.6±0.5 mm for Sx-Sham, P<0.01); (4) pulmonary congestion (LW, 7.55±0.40 mg per gram of body weight for Veh-Lig versus 5.21±0.44 mg per gram of body weight for Veh-Sham, P<0.01), marginally attenuated by Sx (6.54±0.28 mg per gram of body weight for Sx-Lig versus 4.98±0.22 mg per gram of body weight for Sx-Sham, P<0.05); (5) reduction in baroreflex sensitivity (0.443±0.032 ms/mm Hg for Veh-Lig versus 0.860±0.420 ms/mm Hg for Veh-Sham, P<0.01), entirely prevented by Sx (1.217±0.058 ms/mm Hg for Sx-Lig versus 1.345±0.093 ms/mm Hg for Sx-Sham, P=NS).

Conclusions— In early post-MI CHF, sympathectomy only partially attenuated LV dysfunction and entirely prevented baroreflex sensitivity impairment that arises from enhanced sympathetic activity.

Key Words: heart failure • baroreceptors • nervous system, sympathetic

This article has been cited by other articles:

				K. D. Monahan Effect of aging on baroreflex function in humans Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2007; 293(1): R3 - R12. [Abstract] [Full Text] [PDF]

				S. Perlini, I. Ferrero, G. Palladini, R. Tozzi, C. Gatti, M. Vezzoli, F. Cesana, M. B. Janetti, F. Clari, G. Busca, et al. Survival Benefits of Different Antiadrenergic Interventions in Pressure Overload Left Ventricular Hypertrophy/Failure Hypertension, July 1, 2006; 48(1): 93 - 97. [Abstract] [Full Text] [PDF]

				S. Perlini, G. Palladini, I. Ferrero, R. Tozzi, S. Fallarini, A. Facoetti, R. Nano, F. Clari, G. Busca, R. Fogari, et al. Sympathectomy or Doxazosin, But Not Propranolol, Blunt Myocardial Interstitial Fibrosis in Pressure-Overload Hypertrophy Hypertension, November 1, 2005; 46(5): 1213 - 1218. [Abstract] [Full Text] [PDF]

				L. Gao, Z. Zhu, I. H. Zucker, and W. Wang Cardiac sympathetic afferent stimulation impairs baroreflex control of renal sympathetic nerve activity in rats Am J Physiol Heart Circ Physiol, May 1, 2004; 286(5): H1706 - H1711. [Abstract] [Full Text] [PDF]

				H. Bonnemeier, U. K.H. Wiegand, J. Friedlbinder, S. Schulenburg, F. Hartmann, F. Bode, H. A. Katus, and G. Richardt Reflex Cardiac Activity in Ischemia and Reperfusion: Heart Rate Turbulence in Patients Undergoing Direct Percutaneous Coronary Intervention for Acute Myocardial Infarction Circulation, August 26, 2003; 108(8): 958 - 964. [Abstract] [Full Text] [PDF]